5 Health Services Stocks Pushing Industry Growth

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 11 points (0.1%) at 15,533 as of Tuesday, July 30, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,505 issues advancing vs. 1,392 declining with 116 unchanged.

The Health Services industry currently sits up 1.0% versus the S&P 500, which is up 0.2%. A company within the industry that increased today was CareFusion ( CFN), up 1.3%. On the negative front, top decliners within the industry include Express Scripts ( ESRX), down 2.3%, UnitedHealth Group ( UNH), down 0.8% and Cigna ( CI), down 0.6%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. Grifols ( GRFS) is one of the companies pushing the Health Services industry higher today. As of noon trading, Grifols is up $0.25 (0.8%) to $31.55 on light volume. Thus far, 58,836 shares of Grifols exchanged hands as compared to its average daily volume of 623,600 shares. The stock has ranged in price between $31.31-$31.73 after having opened the day at $31.31 as compared to the previous trading day's close of $31.30.

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, and Canada. Grifols has a market cap of $17.4 billion and is part of the health care sector. Shares are up 20.9% year to date as of the close of trading on Monday. Currently there are 2 analysts that rate Grifols a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Grifols as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Grifols Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Hologic Agrees to Sell Blood Screening Business to Grifols for $1.85B

5 Big Dividend Stocks Billionaire John Paulson Loves

3 Stocks Pulling The Health Services Industry Downward

3 Stocks Pushing The Health Services Industry Higher

3 Health Services Stocks Driving The Industry Higher